[go: up one dir, main page]

MX2022011582A - Formas cristalinas de un agonista del receptor farnesoide x. - Google Patents

Formas cristalinas de un agonista del receptor farnesoide x.

Info

Publication number
MX2022011582A
MX2022011582A MX2022011582A MX2022011582A MX2022011582A MX 2022011582 A MX2022011582 A MX 2022011582A MX 2022011582 A MX2022011582 A MX 2022011582A MX 2022011582 A MX2022011582 A MX 2022011582A MX 2022011582 A MX2022011582 A MX 2022011582A
Authority
MX
Mexico
Prior art keywords
farnesoid
receptor agonist
crystalline forms
hydroxyazetidine
metho
Prior art date
Application number
MX2022011582A
Other languages
English (en)
Inventor
Nicholas D Smith
Robert Mansfield
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of MX2022011582A publication Critical patent/MX2022011582A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se describe el agonista del receptor farnesoide X, 3-hidroxiazetidinatrans-1-carboxilato de 4-((4-(1-(terc-butil)-1H-pirazol-4-il)piridin-2-il)((4-(4-metoxi- 3- metilfenil)biciclo[2.2.2]octan-1-il)metil)carbamoil)ciclohexilo , incluidas formas cristalinas y sales, solvatos y formulaciones farmacéuticamente aceptables de este.
MX2022011582A 2020-03-18 2021-03-17 Formas cristalinas de un agonista del receptor farnesoide x. MX2022011582A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991213P 2020-03-18 2020-03-18
PCT/US2021/022790 WO2021188692A1 (en) 2020-03-18 2021-03-17 Crystalline forms of a farnesoid x receptor agonist

Publications (1)

Publication Number Publication Date
MX2022011582A true MX2022011582A (es) 2022-12-13

Family

ID=77771306

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022011582A MX2022011582A (es) 2020-03-18 2021-03-17 Formas cristalinas de un agonista del receptor farnesoide x.
MX2025009319A MX2025009319A (es) 2020-03-18 2022-09-15 Formas cristalinas de un agonista del receptor farnesoide x

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025009319A MX2025009319A (es) 2020-03-18 2022-09-15 Formas cristalinas de un agonista del receptor farnesoide x

Country Status (12)

Country Link
EP (1) EP4121010A4 (es)
JP (2) JP7664278B2 (es)
KR (1) KR20220155356A (es)
CN (1) CN115666521A (es)
AR (1) AR121596A1 (es)
AU (1) AU2021236648A1 (es)
BR (1) BR112022018596A2 (es)
CA (1) CA3171987A1 (es)
IL (1) IL296532A (es)
MX (2) MX2022011582A (es)
TW (1) TW202144332A (es)
WO (1) WO2021188692A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084817B2 (en) 2018-09-18 2021-08-10 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
CN120938937A (zh) 2020-03-18 2025-11-14 伊莱利利公司 法尼醇x受体激动剂的制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
AU2018236275B2 (en) * 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
IL269068B (en) * 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
US11084817B2 (en) * 2018-09-18 2021-08-10 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
WO2020061117A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2020061116A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP2022500391A (ja) * 2018-09-18 2022-01-04 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
CA3172205A1 (en) * 2020-03-18 2021-09-23 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
CN120938937A (zh) * 2020-03-18 2025-11-14 伊莱利利公司 法尼醇x受体激动剂的制剂

Also Published As

Publication number Publication date
MX2025009319A (es) 2025-09-02
JP2025121901A (ja) 2025-08-20
KR20220155356A (ko) 2022-11-22
EP4121010A1 (en) 2023-01-25
US20230147756A1 (en) 2023-05-11
JP2023518399A (ja) 2023-05-01
AR121596A1 (es) 2022-06-22
WO2021188692A1 (en) 2021-09-23
IL296532A (en) 2022-11-01
TW202144332A (zh) 2021-12-01
BR112022018596A2 (pt) 2023-03-07
EP4121010A4 (en) 2024-04-10
CA3171987A1 (en) 2021-09-23
CN115666521A (zh) 2023-01-31
JP7664278B2 (ja) 2025-04-17
AU2021236648A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
MX2022011582A (es) Formas cristalinas de un agonista del receptor farnesoide x.
MX2024012963A (es) Compuestos de modulacion de kras g12d
EP4247807A4 (en) 6,7-DIHYDRO-PYRANO[2,3-D PYRIMIDINE AS INHIBITORS OF THE KRAS G12C MUTANT
CR20230066A (es) Agonistas del glp-1 heterocíclicos
MX2023000835A (es) Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso de este.
MX2022009524A (es) Agonistas heterociclicos de glp-1.
SI2295055T1 (sl) (+)-2-(1-(3-etoksi-4-metoksifenil)-2-metilsulfoniletil)-4-acetilamino- izoindolin-1, 3-dion: Metode uporabe in njegovi sestavki
DK1487461T3 (da) Fremgangsmåder til anvendelse af og præparater omfattende immunomodulatoriske forbindelser til behandling og håndtering af myelodysplastiske syndromer
WO2004066910A8 (en) Controlled release modifying complex and pharmaceutical compositions thereof
MX339071B (es) Almidon pregelatinizado en una formulacion de liberacion controlada.
MX2024007906A (es) Sal farmaceuticamente aceptable y forma cristalina del agonista receptor glp-1 y metodo de preparacion del mismo.
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
TW200726467A (en) Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
NZ564696A (en) Glucocorticoid, indazole, mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP4461370A3 (en) Antiproliferative compounds and second active agents for use in treating multiple myeloma
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
Zanchetti Emerging data on calcium‐channel blockers: the COHORT study
NO20064010L (no) Indazolderivater og farmasoytiske preparater inneholdelse slike
MX2021003083A (es) Formas cristalinas de un agonista del receptor de farnesoide x.
MX2024001829A (es) Derivado de triazol sustituido, metodo de preparacion del mismo, composicion farmaceutica del mismo y uso del mismo.
ZA202204943B (en) Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
MX2025003882A (es) Formulaciones de moduladores del receptor de glucocorticoides
MXPA05011841A (es) Metil-indoles y metil-pirrolopiridinas como agonistas adrenergicos de alfa-1.
EP4438043A3 (en) Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
RU2002110106A (ru) Новые производные пиримидин-2, 4,6-трионов, способ их получения и фармацевтические средства, содержащие эти соединения